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Background
Adoptive T cell therapy (ACT) can promote dramatic
regressions of established cancer, yet durable clinical
responses are observed in only a subset of patients.
ACT provides the opportunity to alter the immune sup-
pressive host environment associated with cancer prior
to introduction of tumor-specific T cells.
Methods
Here, we evaluated the utility of combined whole body
irradiation and agonist anti-CD40 antibody to enhance
ACT-mediated control of established autochthonous
pancreatic tumors.
Results
Sublethal whole body irradiation, a conditioning regimen
associated with donor T cell persistence, had little impact
on donor T cell magnitude or disease outcome, but did
increase T cell persistence. Anti-CD40 conditioning, an
approach known to enhance antigen presenting cell func-
tion and T cell expansion, transiently increased T cell
accumulation in the lymphoid organs and the pancreas,
but failed to eliminate established disease. In contrast,
combined whole body irradiation and anti-CD40 pro-
longed T cell proliferation in the tumor draining lymph
node and dramatically increased accumulation of inter-
feron gamma-producing, PD-1lo donor T cells in the pan-
creas. Dual-conditioning with ACT also induced histologic
regression of established tumors and significantly
increased overall survival. Increased lifespan was entirely
dependent upon T cell transfer, and partially dependent
upon interferon gamma production by donor T cells.
Conclusions
Our results identify the novel combination of two clini-
cally relevant host conditioning approaches that together
with ACT overcome tumor-induced immune suppression
to produce dramatic therapeutic benefits against estab-
lished tumors.
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